Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boeing Co (BA) vs GeneDx Holdings Corp (WGS) Price & Performance

GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Boeing Co vs GeneDx Holdings Corp — how do they compare? Boeing Co trades at $233.45 (market cap $183.99B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: Boeing Co is far larger — about 79.3× GeneDx Holdings Corp's market cap, and Boeing Co pays a 0.03% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

BAWGS
Market Cap
$183.99B$2.32B
Volume
7,591,579
Sector
IndustrialsTechnology
52-Week High
$252.15$167.51
52-Week Low
$179.12$34.51
Enterprise Value
$209.87B$2.35B
Dividend Yield
0.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boeing Co

Boeing (BA) trades at $234.42, up 0.96% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The company reported revenue of $89.46 billion in 2025, turning a net profit of $2.24 billion after years of losses, though margins remain thin. Recent news highlights a strategic deal with Archer Aviation, transferring three subsidiaries for a 19.75% stake, potentially enhancing Boeing's position in autonomous flight technology.

The outlook is cautiously optimistic, with a consensus price target of $284 offering ~21% upside, but risks include high debt, regulatory scrutiny from FAA inspections, and volatile cash flows. Investors should weigh the recovery in commercial aerospace against execution challenges and macroeconomic headwinds.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boeing Co

The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.

Read more on BA

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS